News
STSA
1.100
0.00%
0.000
Webull provides a variety of real-time STSA stock news. You can receive the latest news about Satsuma Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About STSA
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.